Standard BioTools (LAB) Stock Price, News & Analysis

Company Overview

Standard BioTools, Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling. Standard BioTools also offers real-time PCR arrays, microfluidic access arrays and reagents designed to streamline workflows for target validation, drug discovery and translational research.

Headquartered in South San Francisco, Standard BioTools maintains sales and support operations across North America, Europe and Asia, serving a global customer base of life science researchers and clinicians. The company invests in application development and cross-platform software that enables users to integrate proteomic, genomic and imaging data for deeper biological insights.

In October 2023, the company rebranded from Fluidigm to Standard BioTools to reflect its unified approach to multi-omic and spatial biology solutions. Led by an experienced management team with backgrounds in life sciences innovation and instrumentation, Standard BioTools continues to expand its product portfolio and market reach.

Key Stats

• Today's Range: $0.67 to $0.72
• 50-Day Range: $0.68 to $0.94
• 52-Week Range: $0.67 to $1.72
• Volume: 1.57 million shs
• Average Volume: 1.62 million shs
• Market Capitalization: $268.72 million
• P/E Ratio: 3.11
• Dividend Yield: N/A
• Price Target: $1.35
• Consensus Rating: Reduce

Standard BioTools Stock Analysis - MarketRank™

Standard BioTools scored higher than 60% of companies evaluated by MarketBeat, and ranked 388th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Standard BioTools has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Standard BioTools has a consensus price target of $1.35, representing about 97.2% upside from its current price of $0.68.

Amount of Analyst Coverage

Standard BioTools has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Standard BioTools is 3.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Standard BioTools is 3.11, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.41.

Price to Book Value per Share Ratio

Standard BioTools has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.94% of the float of Standard BioTools has been sold short.

Short Interest Ratio / Days to Cover

Standard BioTools has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Standard BioTools has recently increased by 21.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Standard BioTools does not currently pay a dividend.

Dividend Growth

Standard BioTools does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.63

News Sentiment

Standard BioTools has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Standard BioTools this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Standard BioTools insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.81% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/17/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:LAB
• Previous Symbol: NASDAQ:SLGC
• CIK: 1162194
• Web: www.fluidigm.com
• Phone: (650) 266-6000
• Fax: 650-871-7152
• Employees: 620
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Standard BioTools: $1.35
• High Price Target: $1.35
• Low Price Target: $1.35
• Potential Upside/Downside: +97.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.22
• Trailing P/E Ratio: 3.11
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.90 million
• Net Margins: 100.36%
• Pretax Margin: -107.55%
• Return on Equity: -7.57%
• Return on Assets: -6.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.10
• Quick Ratio: 8.80

Sales & Book Value

• Annual Sales: $85.33 million
• Price / Sales: 3.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 392,580,000
• Free Float: 287,329,000
• Market Cap: $268.72 million
• Optionable: Optionable
• Beta: 1.39